A non myeloablative regimen for allografting high-risk patients: Low toxicity, stable engraftment without GVHD, disease control and potential for GVL with adoptive immunotherapy. - Kottaridis, P; Chakraverty, R; Milligan, D; Chakrabarti, S; Robinson, S; Chopra, R; Pettengell, R; Marsh, J; Mahendra, P; Schey, S; Morgan, G; Williams, C; et al. (1999)